Ami Fadia, an analyst from Needham, reiterated the Buy rating on ACADIA Pharmaceuticals. The associated price target was lowered to $28.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ami Fadia’s rating is based on the potential of ACADIA Pharmaceuticals’ existing and future product pipeline despite recent setbacks. Although the ACP-101 did not meet expectations in the Phase 3 COMPASS study, the company’s other products, such as Nuplazid and Daybue, are expected to meet their guidance targets for 2025.
Ami Fadia also anticipates positive developments from ACADIA’s ongoing research, particularly the upcoming data readout from ACP-204’s Phase 2 study in Alzheimer’s Disease Psychosis expected in mid-2026. These factors contribute to a positive outlook for the company’s stock, justifying the Buy rating.
In another report released yesterday, UBS also reiterated a Buy rating on the stock with a $39.00 price target.
Based on the recent corporate insider activity of 27 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ACAD in relation to earlier this year.